Dr. Jessica A. Thomes Pepin
Claim this profileAbbott-Northwestern Hospital
Studies Ovarian Cancer
Studies Ovarian Carcinoma
10 reported clinical trials
26 drugs studied
Area of expertise
1Ovarian Cancer
BRCA1 positive
Stage IV
Stage III
2Ovarian Carcinoma
Stage IV
Stage III
Stage II
Affiliated Hospitals
Clinical Trials Jessica A. Thomes Pepin is currently running
Herceptin Hylecta or Phesgo + Chemotherapy
for Uterine Cancer
This phase III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin Hylecta \[TM\]) or pertuzumab, trastuzumab and hyaluronidase-zzxf (Phesgo \[TM\]) to the usual chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients with HER2 positive endometrial cancer. Trastuzumab and pertuzumab are monoclonal antibodies and forms of targeted therapy that attach to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When trastuzumab or pertuzumab attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Hyaluronidase is an endoglycosidase. It helps to keep pertuzumab and trastuzumab in the body longer, so that these medications will have a greater effect. Hyaluronidase also allows trastuzumab and trastuzumab/pertuzumab to be given by injection under the skin and shortens their administration time compared to trastuzumab or pertuzumab alone. Paclitaxel is a taxane and in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Giving Herceptin Hylecta or Phesgo in combination with paclitaxel and carboplatin may shrink the tumor and prevent the cancer from coming back in patients with HER2 positive endometrial cancer.
Recruiting2 awards Phase 3
Surgical Procedures
for Reducing Ovarian Cancer Risk
This clinical trial evaluates how well two surgical procedures (bilateral salpingectomy and bilateral salpingo-oophorectomy) work in reducing the risk of ovarian cancer for individuals with BRCA1 mutations. Bilateral salpingectomy involves the surgical removal of fallopian tubes, and bilateral salpingo-oophorectomy involves the surgical removal of both the fallopian tubes and ovaries. This study may help doctors determine if the two surgical procedures are nearly the same for ovarian cancer risk reduction for women with BRCA1 mutations.
Recruiting1 award N/A
More about Jessica A. Thomes Pepin
Clinical Trial Related2 years of experience running clinical trials · Led 10 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Jessica A. Thomes Pepin has experience with
- Olaparib
- Cediranib Maleate
- Durvalumab
- Behavioral Dietary Intervention
- Compliance Monitoring
- Exercise Intervention
Breakdown of trials Jessica A. Thomes Pepin has run
Ovarian Cancer
Ovarian Carcinoma
Endometrial Adenocarcinoma
Fallopian Tube Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jessica A. Thomes Pepin specialize in?
Jessica A. Thomes Pepin focuses on Ovarian Cancer and Ovarian Carcinoma. In particular, much of their work with Ovarian Cancer has involved BRCA1 positive patients, or patients who are Stage IV.
Is Jessica A. Thomes Pepin currently recruiting for clinical trials?
Yes, Jessica A. Thomes Pepin is currently recruiting for 2 clinical trials in Minneapolis Minnesota. If you're interested in participating, you should apply.
Are there any treatments that Jessica A. Thomes Pepin has studied deeply?
Yes, Jessica A. Thomes Pepin has studied treatments such as Olaparib, Cediranib Maleate, Durvalumab.
What is the best way to schedule an appointment with Jessica A. Thomes Pepin?
Apply for one of the trials that Jessica A. Thomes Pepin is conducting.
What is the office address of Jessica A. Thomes Pepin?
The office of Jessica A. Thomes Pepin is located at: Abbott-Northwestern Hospital, Minneapolis, Minnesota 55407 United States. This is the address for their practice at the Abbott-Northwestern Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.